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SUMMARY 
Alterations in chromatin structure play a major role in the epigenetic 
regulation of gene expression. Here we describe a step-by-step protocol for 
Differential Viral Accessibility (DIVA), a method for identifying changes in 
chromatin accessibility genome-wide. Commonly used methods to map 
accessible genomic loci have strong preferences towards detecting “open” 
chromatin found at regulatory regions, but are not well suited to study 
chromatin accessibility in gene bodies and intergenic regions. DIVA 
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overcomes this limitation, enabling a broader range of sites to be interrogated. 
Conceptually DIVA is similar to ATAC-seq in that it relies on the integration of 
exogenous DNA into the genome to map accessible chromatin, except that 
chromatin architecture is probed through mapping integration sites of 
exogenous lentiviruses. An isogenic pair of cell lines are transduced with a 
lentiviral vector, followed by PCR amplification and Illumina sequencing of 
virus-genome junctions; the resulting sequences define a set of unique 
lentiviral integration sites which are compared to determine whether genomic 
loci exhibit significantly altered accessibility between experimental versus 
control cells. Experienced researchers will take 6 days to generate lentiviral 
stocks and transduce the target cells, a further 5 days to prepare the Illumina 
sequencing libraries and a few hours to perform the bioinformatic analysis.   
 
 
 
INTRODUCTION 
As alterations in chromatin structure play a pivotal role in the epigenetic 
regulation of gene expression, the ability to examine chromatin structure is critical to 
understanding the molecular basis of gene regulation. A variety of approaches have 
been developed for probing chromatin accessibility, including DNase-seq1, MNase-
seq2, FAIRE-seq3, NA-seq4, RED-seq5 and ATAC-seq6, but, whilst these 
methodologies effectively detect regions of accessible, “open” chromatin, they are 
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less suited to examining changes at “closed” genomic regions that adopt a more 
compact chromatin structure.  
 
Development of DIVA.  
We have recently characterized the Human Silencing Hub (HUSH) complex, along 
with its effector proteins SETDB1 and MORC2, as an epigenetic regulator of 
heterochromatin marked by the repressive H3K9me3 modification7–9. Motivated by a 
desire to examine potential dysregulation of heterochromatin architecture upon loss 
of HUSH function, we developed Differential Viral Integration (DIVA), a genome-wide 
method to profile chromatin accessibility in cultured cells9. Conceptually DIVA is 
similar to ATAC-seq, except that, rather than using transposon integration sites to 
map accessible chromatin, DIVA maps the integration sites of exogenous 
lentiviruses (Fig. 1). Whilst the Tn5 transposase used in ATAC-Seq exhibits a strong 
preference for integration near transcriptional start sites10, HIV-1-derived lentiviral 
vectors utilized in DIVA also target gene bodies and intergenic regions11, thereby 
allowing the DIVA technique to interrogate the architecture of a broader range of  
loci.  
We employed DIVA to compare the chromatin architecture of wild-type and 
MORC2 knockout HeLa cells, identifying a range of loci showing increased viral 
accessibility upon loss of MORC29. In principle a similar genetic approach could be 
used to examine the effect of ablation or overexpression of any epigenetic regulator 
on chromatin architecture. Similarly, if chemical inhibitors targeting an epigenetic 
modifier of interest are available, DIVA could be employed to compare chromatin 
architecture in vehicle versus drug treated cells.  
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Overview of the procedure.  
DIVA involves three phases (Fig. 2). In phase one, lentiviral particles are packaged 
in HEK-293T cells and used to infect the target cells at high multiplicity-of-infection 
(MOI) (Fig. 2a). Following integration of the lentiviruses into the genome of the target 
cells, the goal of phase two is to map the sites of lentiviral integration. Genomic DNA 
is extracted and digested, adaptors are ligated onto the ends of the fragments, and 
then fragments containing proviral DNA are enriched through a linear PCR reaction. 
The linear PCR products are subsequently captured and subjected to exponential 
PCR to generate libraries for Illumina sequencing (Fig. 2b). Finally, in phase three, 
the Illumina sequencing data is used to generate a set of unique lentiviral integration 
sites detected in the population; comparing the pattern of lentiviral integration 
between control and experimental samples reveals loci exhibiting differential 
accessibility (Fig. 2c).  
 
Comparison with other methods.  
When compared to alternative genome-wide high-throughput chromatin accessibility 
assays, a major advantage of DIVA is its ability to assay both accessible and 
inaccessible chromatin simultaneously due to the ability of lentiviruses to integrate 
across gene bodies and intergenic regions (Fig. 3a). In contrast, ATAC-seq and 
MNase-seq, plus the related techniques DNase-seq, NA-seq4 and RED-seq5, all 
employ enzymes which exhibit a strong preference for activity at accessible 
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chromatin regions found at transcriptional start sites (TSSs), and hence are less 
suited to the study of “closed”, genomic regions.  
DIVA requires a similar sequencing depth to that of other chromatin accessibility 
assays6. 30 million uniquely mapped reads per sample are sufficient to identify a 
large number of unique lentiviral integration sites and provide coverage across a 
large mammalian genome; downsampling analysis of our data9 suggests that around 
10 million uniquely mapped reads per condition would be the minimum sequencing 
depth at which meaningful conclusions could be drawn from a DIVA experiment (Fig. 
3b-d). As ATAC-seq involves the purchase of an expensive Illumina kit and often 
requires deeper sequencing due to mitochondrial DNA contamination, DIVA is likely 
to be more cost-effective than a typical ATAC-seq experiment. Indeed, as the 
majority of the reagents required are inexpensive and the depth of Illumina 
sequencing required is modest, the overall cost of a DIVA experiment is relatively 
low.   
 
 However, DIVA is also subject to some technical limitations. DIVA requires a 
large number of cells (~6 million) to ensure sufficient coverage of the genome, 
whereas ATAC-seq can reveal regions of open chromatin using just 500 cells10, and 
has even been adapted to analyze single cells12. Furthermore, in contrast to the 
simple and rapid sample preparation required for ATAC-seq, DIVA involves a more 
complex and time-consuming library generation protocol which also relies on the 
availability of a BSL-2 tissue culture room. Thus, whilst ATAC-seq retains clear 
advantages over DIVA for researchers interested only in interrogating sites of open 
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chromatin, DIVA may be better suited to examining changes in heterochromatic 
regions, gene bodies and intergenic regions.  
 
Limitations of the method.  
There are a number of limitations to the current version of the DIVA protocol. First, 
sufficient coverage of a large mammalian genome can only be obtained if millions of 
independent lentiviral integration sites are mapped. This relies on achieving a high 
multiplicity of infection (MOI) when transducing the target cells with the lentiviral 
vector, which may not be possible in cell lines or primary cells which are difficult to 
transduce. Second, DIVA may not be suitable for comparisons between non-isogenic 
cell lines, where it is difficult to control for differences in the abundance or activity of 
other factors besides changes in chromatin architecture that may influence viral 
integration preferences. For example, differences in the abundance of the 
LEDGF/p75 protein, a cellular tethering factor for HIV-1-based lentiviruses13, could 
result in altered patterns of viral integration that are not related to altered chromatin 
accessibility. Finally, DIVA may be less well suited to measuring decreases in 
chromatin accessibility: whereas increased accessibility is revealed by an increase in 
the number of viral integration sites detected at a given locus, decreased 
accessibility must be inferred from the absence of detection. However, provided that 
sufficient numbers of lentiviral integration sites are mapped across such regions, in 
principle a reproducible decrease in the number of lentiviral integration sites as 
measured by DIVA should be indicative of decreased chromatin accessibility.  
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Applications.  
A critical part of the DIVA protocol is the mapping of the sites of integration of 
exogenous lentiviral DNA on a large scale. The linear amplification-mediated 
polymerase chain reaction (LAM-PCR) approach described here was adapted from 
that originally devised by the Brummelkamp laboratory14, and has been used 
extensively to map the integration sites of gene-trap retroviral vectors to analyze 
forward genetic screens in haploid human cell lines15–17. This technique is likely to be 
applicable in other experimental settings, and, employing appropriately redesigned 
primers, the LAM-PCR protocol used for DIVA could be readily adapted to locate any 
exogenously integrated DNA in large mammalian genomes. 
 
 
Experimental design 
Cell lines. DIVA was developed as a comparative method to reflect differences in 
chromatin accessibility between a control and treated cell line. Therefore we 
recommend that DIVA be performed in isogenic cell lines (step 8), as differences in 
the abundance or activity of cellular factors that affect lentiviral integration 
preferences could lead to altered integration patterns that are not indicative of 
changes in chromatin structure.  
Choice of lentiviral vector. In principle any standard lentiviral vector could be used 
to perform a DIVA experiment (step 3). There are two particular advantages to the 
pHRSIN-PSFFV-mCherry vector that we employed9: (1) expression of the mCherry 
fluorescent protein allows the transduction of the target cells to be easily monitored 
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by flow cytometry, and (2) the arrangement of NlaIII restriction sites in the vector is 
favorable for efficient LAM-PCR amplification of virus-genome junctions (Box 1). 
Choice of restriction enzyme. This protocol uses a single restriction enzyme, 
NlaIII, to digest the genomic DNA isolated from the transduced target cells (step 16). 
NlaIII cleaves at its 4 bp recognition site 5’-CATG-3’, which occurs every ~200 bp in 
the genome. A proportion of all the lentiviral integration sites in the transduced 
population will lie either too close or too far from an NlaIII cleavage site to be 
mapped, however; therefore, to increase the coverage obtained, the genomic DNA 
could also be digested (in separate reactions) with additional ‘4-cutter’ restriction 
enzymes that are not affected by CpG methylation, such as MseI or MluCI. Adapting 
the protocol for additional enzyme(s) would require the design of modified adaptor 
oligonucleotides with the appropriate cohesive ends; in these cases this would 
require the removal of the CATG overhang from the 3’ end of the NlaIII-BSA 
oligonucleotide and addition of a TA (MseI) or an AATT (MluCI) overhang to the 5’ 
end of the TSA oligonucleotide (Table 1). Care also needs to be taken to ensure that 
the lentiviral vector used will not itself be cleaved by the restriction enzyme in a 
manner that would prevent PCR amplification of the virus-genome junction (see Box 
1 for further details).  
Production of high-titer lentivirus. In order to gain sufficient coverage of the 
genome, millions of lentiviral integration sites must be mapped in each cell type. It is 
therefore critical that high-titer lentivirus is produced (steps 1-7). We recommend 
using low passage HEK 293T cells and endotoxin-free DNA vectors. To optimize the 
conditions for virus production, a lentiviral vector encoding a fluorescent protein can 
be used. HEK 293T cell seeding density, DNA:TransIT ratio, the number of cells to 
be transduced and the amount of viral supernatant used for the transduction will all 
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affect the transduction efficiency, and hence all of these parameters may need to be 
optimized to achieve maximum transduction efficiency for DIVA. Enhanced 
transduction efficiency can also be achieved by concentrating the viral supernatant, 
for example using Lenti-X Concentrator (Clontech, cat. no. 631231), or by performing 
the transduction in the presence of Polybrene at a final concentration of 8 μg/ml.   
Sequencing depth required. We used a single run of an Illumina HiSeq 2500 
machine in rapid run mode to generate the sequencing data for our DIVA experiment 
in HeLa cells9, which yielded approximately 50 million uniquely mapped reads for 
each condition. An analysis of the sequencing depth requirements for DIVA are 
presented in Fig. 3b. This analysis suggests that 30-50 million uniquely mapped 
reads are sufficient to map the majority of unique lentiviral integration sites present in 
a DIVA library, while 10 million uniquely mapped reads per condition should be 
considered the minimum required to generate meaningful data. We recommend 
single-end 50 bp reads to minimize the cost of the experiment (step 43).  
Data analysis. This protocol uses the Seqmonk 
(https://www.bioinformatics.babraham.ac.uk/projects/seqmonk/) application to 
analyze the Illumina sequencing data (steps 44-70). Seqmonk is a powerful genome 
browser application that allows both the visualization and quantitation of mapped 
sequence data. Its graphical user interface is ideal for biologists with limited 
programming experience; experienced bioinformaticians, however, could readily 
automate these steps using standard tools (for example, the BedTools suite18).  
  
Level of expertise required. Successful DIVA experiments can be performed by 
competent graduate students with relevant experience in cell culture and molecular 
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biology techniques and a basic level of Unix knowledge. As the LAM-PCR protocol to 
map viral integration sites is relatively challenging, however, we would not 
recommend it be attempted by users inexperienced in molecular biology techniques. 
The steps described in this protocol do not require any non-standard reagents or 
equipment, and hence could be adopted by any laboratory with access to a BSL-2 
tissue culture room and a next-generation sequencing facility. Previous experience 
working with lentiviral vectors would be beneficial but not essential, as the technique 
could be easily mastered after a short induction.  
  
 
 
 
 
 
 
 
 
 
MATERIALS 
REAGENTS 
11 
  
• Target cell type of choice plus appropriate culture media. We have used HeLa cells 
(ATCC CCL-2), cultured in RPMI 1640 (see Reagent Setup).  
CRITICAL DIVA relies on a comparison between two experimental conditions, and 
therefore a control and a treated cell line is required. For example, we used DIVA to 
compare wild-type versus mutant HeLa cells9.   
! CAUTION The cell lines used in your research should be regularly checked to 
ensure they are authentic and are not infected with mycoplasma. 
•   HEK293T cells (ATCC CRL-1573) 
! CAUTION The cell lines used in your research should be regularly checked to 
ensure they are authentic and are not infected with mycoplasma. 
• RPMI 1640 (Thermo Fisher Scientific, cat. no. 11875093) 
• DMEM (Thermo Fisher Scientific, cat. no. 11965092) 
• Opti-MEM I Reduced Serum Media (Thermo Fisher Scientific, cat. no. 31985070) 
• Fetal bovine serum (HyClone, cat. no. SH30071.03) 
• Penicillin-streptomycin (Thermo Fisher Scientific, cat. no. 15140122) 
• Trypsin-EDTA (0.25%) (Thermo Fisher Scientific, cat. no. 25200056) 
• Lentiviral transfer vector (Box 1). We have used the pHRSIN-PSFFV-mCherry vector, 
which encodes mCherry from the spleen focus-forming virus (SFFV) long terminal 
repeat (LTR) promoter, allowing transduced cells to be fluorescently marked 
(Addgene, cat no. 74670). 
• Lentiviral packaging plasmids pMD2.G and psPAX2 (Addgene, cat. no. 12259 and 
12260) 
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• TransIT-293 transfection reagent (Mirus, cat. no. MIR 2700) 
• Polybrene (Sigma-Aldrich, cat. no. H9268) 
• PBS (Thermo Fisher Scientific, cat. no. 10010023) 
• Gentra Puregene Cell Kit (Qiagen, cat. no. 158767) 
• NlaIII (NEB, cat. no. R0125L) 
• Ultrapure water (Thermo Fisher Scientific, cat. no. 10977015) 
• Agencourt AMPure XP beads (Beckman Coulter, cat. no. A63880) 
• Oligonucleotide adaptors (Sigma-Aldrich; see Table 1 for oligonucleotide 
sequences and Reagent Setup for preparation). 
• 10x NEB buffer 2 (NEB, cat. no. B7002S) 
• T4 DNA ligase (NEB, cat. no. M0202S) 
• Biotinylated linear PCR primer (Sigma-Aldrich; see Table 1 for oligonucleotide 
sequences) 
• Accuprime Taq DNA polymerase (Thermo Fisher Scientific, cat. no. 12339016) 
• dNTPs (NEB, cat. no. N0447L) 
• Streptavidin Dynabeads M-280 (Thermo Fisher Scientific, cat. no. 11205D) 
• Ethanol, Absolute (200 Proof), Molecular Biology Grade (Thermo Fisher Scientific, 
cat. no. BP2818500) 
• 5 M NaCl (Thermo Fisher Scientific, cat. no. 24740011) 
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• 1 M Tris-HCl pH 7.5 (Thermo Fisher Scientific, cat. no. 15567027) 
• 0.5 M EDTA (Thermo Fisher Scientific, cat. no. AM9260G) 
• Tween-20 (Sigma-Aldrich, cat. no. P9416) 
• Exponential PCR primers (Sigma-Aldrich; see Table 1 for oligonucleotide 
sequences) 
• Bioanalyzer High Sensitivity DNA Kit (Agilent, cat. no. 5067-4626) 
 
 
TABLE 1 | Oligonucleotides required for DIVA.  
Oligo name Sequence 5’ – 3’ Purpose Step used
TSA CCTATAGTGAGTCGTATTATATGAGTAGTACCATGGGAAC Top strand adaptor 
23 
NlaIII-BSA GTTCCCATGGTACTACTCATATAATACGACTCACTATAGGCATG Bottom strand adaptor 
Bio-Pack_F [Biotin]-CTTTCGCTTTCAAGTCCCTGTTCG Linear PCR primer 25 
P5-HIV1_F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACG
ACGCTCTTCCGATCTGATCTGGTCTAACCAGAGAG 
 
Exponential PCR 
primers 
(X=index bases) 
34 P7-
Adaptor_R  
CAAGCAGAAGACGGCATACGAGAXXXXXXXGTGACTGGAGTTC
AGACGTGTGCTCTTCCGATCTGTTCCCATGGTACTACTCATATA
ATACG 
 
ISP CTTGTCTTCGTTGGGAGTGAATTAGCCCTTCCA 
 
Illumina sequencing 
primer 
43 
 
 
EQUIPMENT 
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• Syringe (VWR, cat. no. 309646) 
• 0.45 micron syringe filters (Corning, cat. no. 431220) 
• 5 ml polypropylene round-bottom tube for flow cytometry (Corning, cat. no. 352002) 
• 6-well cell culture plates (for example, Thermo Fisher Scientific cat. no. 140675) 
• Cell culture incubator (37°C, 5% CO2, 90% humidified) (for example, Thermo 
Fisher Scientific cat. no. 51026332)  
• Cell culture hood (for example, Thermo Fisher Scientific cat. no. 51023607) 
• Centrifuge (for example, Eppendorf cat. no. 51026332) 
• Flow cytometer (for example, BD LSRFortessa, BD Biosciences cat. no. 649225) 
 • Thermocycler (for example, C1000 Touch Thermal Cycler, Bio-Rad cat. no. 
1851196) 
• Nanodrop spectrophotometer (for example, Thermo Fisher Scientifc cat. no. ND-
2000) 
• Orbital shaker (for example, Eppendorf cat. no. 5382000023) 
• Microcentrifuge (for example, Fisher Scientific cat. no. 05-400-006) 
• 0.2 ml PCR tubes (for example, Fisher Scientific cat. no. Fisher Scientific cat. no. 
14-222-252) 
• 1.5 ml microcentrifuge tubes (for example, Eppendorf cat. no. 022363204)  
• Magnetic rack (for example, Thermo Fisher Scientifc cat. no. 15567027) 
• Bioanalyzer (Agilent, cat. no. G2939BA) 
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• Computer running Unix/Linux distribution with at least 4 GB of RAM and the 
following software installed: 
• Fastqc (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) 
• Fastx toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) 
• Samtools (http://www.htslib.org/) 
• Bowtie 2 (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml) 
• Seqmonk (https://www.bioinformatics.babraham.ac.uk/projects/seqmonk/) 
 
 
REAGENT SETUP 
Cell culture medium. To make up complete DMEM and RPMI cell culture medium, 
in a cell culture hood add 50 ml of FBS (10% vol/vol final) and 5 ml of Penicillin-
Streptomycin solution to 500 ml of cell culture medium and mix thoroughly by 
inverting. Media should be stored at 4°C and discarded if unused after approximately 
one month. 
70% (vol/vol) ethanol. Add 0.3 volumes of ultrapure water to 0.7 volumes of stock 
100% ethanol solution and mix by inverting. The solution can be kept tightly capped 
at room temperature (20°C-25°C). 
Anneal adaptors. Dilute the 10x NEB buffer 2 two-fold by adding an equal volume 
of ultrapure water. Resuspend the TSA (Top Strand Adaptor; Table 1) and NlaIII-
BSA (Bottom Strand Adaptor; Table 1) oligonucleotides in 5x NEB buffer 2 at a final 
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concentration of 100 µM. Then add 50 µl of each oligonucleotide to a PCR tube, mix 
by pipetting, and anneal by placing the tube in a thermocycler and running the 
following program: 
Step Denature Anneal Hold 
1 95ºC, 5 min   
2  Slow cool (0.1ºC/s) to 4ºC  
3   4ºC 
 
Annealed adaptors can then be stored indefinitely at -20ºC. 
PBS + 0.5% (wt/vol) BSA. Weigh out 0.25 g BSA, dispense into a 50 ml plastic 
tube, and add 50 ml PBS. Mix gently by inverting. Place in a water bath at 37ºC for 
30 min to dissolve fully. This solution should be made fresh on each occasion. 
20% (vol/vol) Tween-20. Add 4 volumes of distilled water to 1 volume of Tween-20 
and mix gently by inverting until the solution is homogeneous. The solution can then 
be stored for months at room temperature when protected from light. 
2x B&W buffer. In a 500 ml bottle, add 200 ml 5 M NaCl, 5 ml 1M Tris-HCl pH 7.5 
and 1 ml 0.5 M EDTA. Make up to a total volume of 500 ml with distilled water and 
mix by inverting. The solution can be stored for months at room temperature. 
1x B&W buffer. In a 500 ml bottle, add 250 ml 2x B&W buffer and 250 ml distilled 
water and mix by inverting. The solution can be stored for months at room 
temperature. 
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2x B&W buffer + 0.2% (vol/vol) Tween-20. Pipette 500 µl of 20% Tween-20 into 50 
ml 2x B&W buffer and mix by inverting. The solution can be stored for months at 
room temperature. 
1x B&W buffer + 0.1% (vol/vol) Tween-20. Pipette 250 µl of 20% (vol/vol) Tween-
20 into 50 ml 1x B&W buffer and mix by inverting. The solution can be stored for 
months at room temperature. 
Software setup. Follow the online installation instructions to install Fastqc, the fastx 
toolkit and Bowtie 2 programs onto the linux computer. These need to be added to 
PATH environment variable in order to successfully execute the commands in the 
protocol; detailed instructions on how to do this can be found in the online 
documentation for each tool. Seqmonk can be installed on a computer running any 
operating system. 
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PROCEDURE 
Generation of lentivirus stocks. • TIMING 4 days  
1. After thawing a frozen vial of HEK 293T cells, allow 2-3 days for the cells to 
recover. Then trypsinize the stocks of HEK 293T cells, and seed 6x105 cells in 
each well of a 6-well plate in complete DMEM growth media. Grow overnight 
(~16 h-20 h) to achieve 70% confluency. 
The following morning, perform a triple transfection of the HEK 293T cells to 
generate lentivirus. For each well of HEK 293T cells to be transfected, perform the 
following procedure (Steps 2-6) [AU: Editor has changed text. Please check if it is 
ok.] 
 
2.  Pipette 200 μl Opti-MEM into a sterile 1.5 ml microcentrifuge tube. Then add 
7.5 μl TransIT-293 reagent and mix thoroughly by pipetting. Incubate at room 
temperature for 5 min. 
3. During the incubation, pipette 50 μl Opti-MEM into a second sterile 1.5 ml 
microcentrifuge tube. Then add the following amounts of plasmid DNA: 1 μg 
lentiviral transfer vector, 0.7 μg psPAX2 and 0.3 μg pMD2.G. Mix by pipetting. 
4. Add the TransIT-293/Opti-MEM mix from Step 2 to the DNA/Opti-MEM mix 
from Step 3 and mix gently but thoroughly by pipetting. Incubate at room 
temperature for 20 min. 
5. During the incubation, aspirate media from HEK 293T cells from Step 1 and 
replace with 2 ml fresh DMEM per well. Pipette slowly onto the side of the well 
to minimize cell detachment. 
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6. Add the 250 μl of DNA/TransIT-293/Opti-MEM mix from Step 4 dropwise to 
the HEK 293T cells. Rock the plate gently back and forth to evenly distribute 
transfection complexes. Return to 37°C incubator for 48 hours.  
! CAUTION Users should familiarize themselves with their institutional 
guidelines for handling lentivirus. If appropriate, cells should be transferred to 
a BSL-2 tissue culture room at this point. 
7. Harvest viral supernatant. Pipette media off of the cells and into a syringe 
attached to a 0.45 µm filter. Insert the plunger and gently force the viral 
supernatant through the filter into a sterile collection tube. 
■ PAUSE POINT Viral supernatants can be aliquoted in 1.5 ml 
microcentrifuge tubes and stored at -80ºC for several months with minimal 
loss of activity. 
 
Lentiviral Transduction. • TIMING 3 days 
8.  Seed target cells for transduction. For HeLa cells, seed 1x106 cells in each 
well of a 6-well plate in 2 ml complete RPMI growth medium (a total of 6x106 
cells in 12 ml growth medium). Return to the 37°C incubator for 5 hours.  
▲ CRITICAL STEP Both control and treated cells need be seeded to allow 
for parallel transduction. Continue to culture some wild-type target cells, as 
these will be required as a control sample when estimating transduction 
efficiency at Step 14. 
9. Transduce target cells with lentivirus. Defrost the viral supernatant from Step 
7 and add to target cells. For HeLa cells aspirate the 2 ml of growth media 
and replace it with 1.5 ml of viral supernatant.  
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10. (OPTIONAL) To maximize transduction efficiency, Polybrene (to a final 
concentration of 8 μg/ml) can be added with the virus and/or cells can be spun 
following addition of virus (800 x g, 60 min, 37°C).  
11. Three hours later, aspirate and discard viral supernatant from the cells and 
replace with complete growth media. Return to 37°C incubator overnight.  
12. Repeat transduction of target cells. To increase the overall multiplicity of 
infection achieved, 24 h after the initial transduction repeat the transduction 
process described in steps 9 - 11.   
13. Harvest transduced cells. 24 h after the second transduction, trypsinize cells 
using 0.5 ml of Trypsin-EDTA per well, quench with an equal amount of RPMI 
media, pool and pipette into 50 ml conical tube. Pipette a few drops of the cell 
suspension into a round-bottom 5 ml polypropylene tube for flow cytometry 
analysis9 (Step 14). Then pellet the remainder by centrifugation (500 x g, 5 
min, 4°C), wash the cells once by resuspending the pellet in 50 ml PBS and 
repeating the centrifugation (500 x g, 5 min, 4°C). Finally remove the 
supernatant and resuspend the pellet in 3 ml Cell Lysis Buffer from the Gentra 
Puregene Cell Kit.  
■ PAUSE POINT According to the manufacturer, cell lysates can be stably 
stored at room temperature for at least two years. 
14. Verify transduction efficiency by flow cytometry. If the lentiviral vector used 
expresses a fluorescent marker, then the transduction efficiency of the target 
cells can be assayed by flow cytometry. Setup the instrument using 
untransduced target cells, and then analyze the aliquot of transduced cells 
from Step 13. If high-level transduction has been achieved, then close to 
100% of the cells should be positive for expression of the fluorescent protein.   
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? TROUBLESHOOTING 
 
LAM-PCR amplification of virus-genome junctions. • TIMING 5 days  
15. Extract genomic DNA from cell lysates. Follow the Gentra Puregene Cell Kit 
manual protocol for genomic DNA extraction from cultured cell lysates from 
Step 13. Resuspend the final DNA pellet in 500 μl DNA hydration solution. 
■ PAUSE POINT Genomic DNA can be stored stably for years at 4°C. 
16. Digest genomic DNA with NlaIII. Measure the DNA concentration using a 
Nanodrop spectrophotometer. Take half of the DNA out for restriction enzyme 
digestion and keep the other half at 4°C as a back-up. For each 10 μg of DNA 
to be digested, set up the following reaction in a 1.5 ml microcentrifuge tube:  
Component (add in this order) Amount Final concentration 
Genomic DNA 10 µg  0.1 µg µl-1 
10x NEB CutSmart buffer 10 µl 1x 
ddH2O Up to 90 µl  
NlaIII (10 units µl-1) 10 µl 1 unit µl-1 
Total volume 100 µl  
 
For example, if in total 200 μg of DNA was extracted, digest 10 μg of DNA in 10 
separate digestion reactions. Incubate all tubes at 37°C overnight. 
? TROUBLESHOOTING 
17. Purify and concentrate the digested DNA using a spin column. Follow the 
Qiagen PCR purification kit protocol. To avoid exceeding the binding capacity 
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of the columns, perform a separate purification for each 10 μg of digested 
DNA. Elute the DNA from each column in 30 μl of ultrapure water, and pool all 
of the eluted material in a fresh 1.5 ml microcentrifuge tube. Alternatively, a 
standard phenol/chloroform extraction followed by ethanol precipitation19 
could be used to purify all of the DNA in a single process.  
■ PAUSE POINT Digested DNA can be stored at -20°C. 
18. Size selection to enrich for large DNA fragments that contain virus-genome 
junctions. Vortex the stock solution of Agencourt AMPure XP beads 
thoroughly. Add 0.5 volumes of beads to the pooled digested DNA solution 
from Step 17 and mix well by pipetting. Incubate for 5 min at room 
temperature.  
19. Place the tube on the magnetic stand and wait until the beads are collected by 
the magnet on the back of the tube. Then remove the supernatant and 
discard. 
20. Add 500 μl of 70% (vol/vol) ethanol to wash the beads. Aspirate, and discard, 
and repeat the wash step. Allow the beads to air-dry for a few minutes. 
21. Remove the tube from the magnet. Add 100 μl of ultrapure water and pipette 
to resuspend the beads. Incubate for 5 min at room temperature. 
22. Place the tube back on the magnet. Wait for the magnet to collect the beads 
on the back of the tube (~ 1 min). Collect the supernatant containing the 
eluted DNA into a fresh 1.5 ml microcentrifuge tube, and measure the 
concentration of the sample using a nanodrop spectrophotometer. Typical 
recovery would be about one-third of input DNA. 
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23. Ligate annealed adaptors to the size-selected DNA fragments. For each 3 μg 
of DNA, set up the following reaction in a 0.2 ml PCR tube: 
Component (add in this order) Amount Final concentration 
Size-selected, NlaIII-digested genomic DNA 3 µg  0.06 µg µl-1 
Annealed adaptor (50 µM) 5 µl 5 µM 
10x NEB T4 Ligase buffer 5 µl 1x 
ddH2O Up to 48 µl  
T4 DNA ligase (400 units µl-1) 2 µl 16 units µl-1 
Total volume 50 µl  
 
Incubate at 16°C overnight in a PCR instrument. 
24. Clean-up the ligated DNA using Agencourt Ampure XP beads. Pool all of the 
ligation reactions in a 1.5 ml microcentrifuge tube, add 0.7 volumes of beads 
and follow the procedure described in steps 18-22.   
▲ CRITICAL STEP This clean-up step removes un-ligated adaptors from the 
sample, which otherwise decrease the efficiency of subsequent PCR steps. 
■ PAUSE POINT Ligated DNA can be stored indefinitely at -20°C. 
 
25. Amplify virus-genome junctions by linear PCR. Measure the concentration of 
adaptor-ligated DNA using a Nanodrop spectrophotometer; the total amount 
of DNA should be roughly equivalent to the total amount of input DNA. To 
amplify the material, for each 2 μg of adaptor-ligated DNA, make up the 
following mix: 
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Component (add in this order) Amount Final concentration 
Adaptor-ligated genomic DNA 2 µg  0.04 µg µl-1 
Accuprime buffer II (10x) 5 µl 1x 
Bio-Pack_F (Table 1;0.25 µM) 1 µl 5 nM 
ddH2O Up to 49.6 µl  
Accuprime Taq polymerase (2 U µl-1) 0.4 µl 0.016 U µl-1 
Total volume 50 µl  
 
Run the following thermocycler program: 
Step Denature Anneal Extend Hold 
1 94ºC, 5 min    
2-200 94ºC, 60 s 55ºC, 45 s 68ºC, 90 s  
201   68ºC, 7 min  
202    4ºC 
 
■ PAUSE POINT PCR products can be stored indefinitely at -20°C. 
? TROUBLESHOOTING 
 
26.  Capture biotinylated PCR products onto streptavidin-coated magnetic beads. 
Pool all of the linear PCR reactions into a single 1.5 ml microcentrifuge tube. 
Estimate the total volume using a pipette. 
27. Prepare streptavidin beads. Vortex the tube of beads thoroughly, and then 
pipette 5 µl of beads per PCR reaction (ie. 40 µl beads total for 8 PCR 
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reactions) into a 1.5 ml microcentrifuge tube. Block the beads by collecting the 
beads on the magnet for approximately 1 min. Aspirate the supernatant, 
discard and resuspending the beads in PBS + 0.5% (wt/vol) BSA.  
28. Incubate for 30 min at room temperature, inverting the tube occasionally to 
prevent the beads from sinking.  
29. Collect the beads on the magnet for approximately 1 minute, wash once with 
1 ml 1 x B&W buffer, and discard. Then resuspend the beads in 2 x B&W 
buffer + 0.2% (vol/vol) Tween-20; the volume of buffer should be half that of 
the volume of the pooled PCR products  
30. Add the pooled PCR products from Step 26 to the beads from Step 29, and 
mix thoroughly by pipetting. Incubate for 2 h at room temperature, shaking at 
1100 rpm in an orbital shaker to prevent the beads from sinking.  
31. To wash unbound material from the streptavidin beads, place the tube on the 
magnet to collect the beads, and then remove the supernatant. (Store the 
initial supernatant at -20°C as a back-up; this could be re-amplified in a further 
linear PCR reaction later if necessary).  
32. Add 1 ml of 1x B&W + 0.1% (vol/vol) Tween-20 to the beads, resuspend by 
pipetting, and return the tube to the orbital shaker at 1100 rpm for 10 min.  
33. Wash the beads thoroughly by repeating steps 31 and 32 ten times. 
■ PAUSE POINT Beads can be stored in 1x B&W + 0.1% Tween-20 at 4°C 
for several weeks. 
 
34.  Generate llumina sequencing libraries through an on-bead exponential PCR 
reaction. Prepare the PCR mastermix on ice. In total, perform the same 
number of independent exponential PCR reactions as the number of linear 
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PCR reactions performed in step 25. The following mix details the 
components for one reaction: 
Component (add in this order) Amount (µl) Final concentration 
Accuprime buffer II (10x) 5 1x 
P5-HIV1_F (Table 1; 100 µM) 0.25 0.5 µM 
P7-Adaptor_R (Table 1; 100 µM) 0.25 0.5 µM 
ddH2O Up to 49.4  
Accuprime Taq polymerase (2 U µl-1) 0.6 0.024 U µl-1 
Total volume 50  
 
For example, if 8 separate linear PCR reactions were performed in step 25, multiply 
each of the values above by 8 to make up an 8x mastermix of 400 μl total volume.    
35. Collect the streptavidin beads from Step 33 on the magnet, and perform one 
final wash with PBS. Then collect the beads on the magnet, aspirate the PBS, 
and resuspend the beads in all of the PCR mastermix. Distribute 50 µl of the 
bead/PCR mix into each tube of an 8-strip PCR tube. 
36. Run the following thermocycler program: 
Step Denature Anneal Extend Hold 
1 94ºC, 2 min    
2-11 94ºC, 30 s 55ºC, 30 s 68ºC, 90 s  
12   68ºC, 7 min  
13    4ºC 
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37. Carefully remove the tubes from the PCR machine and place on ice. Without 
disturbing the pellet of beads, remove 15 μl of the supernatant from each of 
the reactions and pool into a separate 1.5 ml tube kept on ice. This is the 10 
cycle sample.  
38. Return the remaining PCR reaction mix to the thermocycler for a further four 
cycles of PCR: 
Step Denature Anneal Extend Hold 
1 94ºC, 2 min    
2-5 94ºC, 30 s 55ºC, 30 s 68ºC, 90 s  
6   68ºC, 7 min  
7    4ºC 
 
39. Again, carefully remove 15 μl of the supernatant from each of the reactions 
and pool into a separate 1.5 ml tube kept on ice. This is the 14 cycle sample. 
Then return the tubes to the thermocycler for a final 4 cycles of PCR:  
Step Denature Anneal Extend Hold 
1 94ºC, 2 min    
2-5 94ºC, 30 s 55ºC, 30 s 68ºC, 90 s  
6   68ºC, 7 min  
7    4ºC 
  
40. Remove all of the remaining volume (including the beads) from the PCR 
reactions and pool into a separate 1.5 ml tube kept on ice. To remove the 
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beads, place the tube on the magnet for 2 min and transfer the supernatant 
into a fresh tube. This is the 18 cycle sample. 
41. Perform a final clean-up of the Illumina libraries. For each of the samples (10 
cycles, 14 cycles and 18 cycles), perform an Agencourt AMPure XP bead 
clean-up as described in steps 18-22, using 0.8 volumes of beads. Elute in 20 
µl of ultrapure water. 
■ PAUSE POINT Sequencing libraries can be stored indefinitely at -20°C. 
42. Validate the lllumina sequencing libraries using an Agilent Bioanalyzer. Run 1 
µl of each of the sequencing libraries on a DNA High Sensitivity Chip. The 
library electropherogram should reveal a broad size distribution between ~240 
bp and ~600 bp, with minimal adaptor dimer contamination at ~120 bp. 
? TROUBLESHOOTING 
43. Submit optimal sample for Illumina sequencing. Using the Bioanalyzer 
software, quantify the concentration of the DNA of the correct size (between 
~240 bp and ~600 bp). Choose the sample which has been subjected to the 
lowest number of PCR cycles, yet still exceeds the minimum amount required 
by your sequencing facility. Submit the final libraries for Illumina sequencing, 
along with a custom sequencing primer that binds to the extreme end of the 
lentiviral 5’LTR (ISP, in our case; see Table 1). We generated 50 bp single-
end sequence reads using an Illumina HiSeq2500 machine.  
? TROUBLESHOOTING 
■ PAUSE POINT Analysis of sequencing data can be performed at any time. 
 
Mapping of Illumina reads and identification of genomic loci exhibiting 
differential accessibility. • TIMING <1 day  
29 
  
44. Copy the output fastq sequencing files generated by the Illumina sequencing 
run to the hard drive of the Linux computer. 
45. Run fastqc to check the run. Navigate to the folder containing the sequencing 
files, open a terminal window, and type the following command after the $ 
sign: 
$ fastqc inputfile.fastq 
(where inputfile is the name of the file to be analyzed).  
? TROUBLESHOOTING 
46. Perform an adaptor trim to remove adaptor sequences from the 3’ ends of 
reads. Type the following command: 
$ fastx_clipper –a CCTATAGTGAGTCGTA –l 18 –v –i inputfile.fastq –o 
outputfile_trimmed.fastq 
(where inputfile is the name of the file to be analyzed and outputfile_trimmed 
is the desired name of the output fastq file containing the trimmed reads).  
47. Map to the human genome using Bowtie 2. Type the following command: 
$ bowtie2 –t –x GRCh38 –U inputfile_trimmed –S ouputfile.sam 
(where GRCh38 is the basename of the Bowtie2 index, inputfile_trimmed is 
the file of trimmed reads from step 46, and outputfile is the desired name of 
the output sam file containing the mapped reads). 
48. To save disk space, compress the output sam file to a bam file by typing: 
$ samtools view –b  ouputfile.sam > outputfile.bam 
 
49. Import the resulting bam file into SeqMonk. The following can be performed 
on any operating system. Navigate to the folder containing the unzipped 
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SeqMonk installation files, and launch the program by running the SeqMonk 
executable file. 
50. From the File menu, select New Project. From the resulting dialog box, click 
the ‘Import Genome From Server’ button and select the genome build to 
which the data was mapped (GRCh38 in this example). Then click on ‘Start 
New Project’ to initialize the project.  
51. To load the data, from the ‘File’ tab select ‘Import Data’ and then click on 
‘BAM/SAM’. Select the location of the relevant sam or bam file(s) from Step 
47 or Step 48 on your computer, and then click ‘OK’. 
52. Specify import options: set ‘Remove duplicate reads’ to ‘Yes’ and ‘Min 
mapping quality’ to ‘20’. Click ‘OK’.  
 
53. Collapse the sequencing reads into a set of unique sites of lentiviral 
integration. Using Seqmonk’s import function, from the ‘File’ tab, choose 
‘Import Data’ and then ‘Visible Data Stores’.  
54. Set ‘Extend reads by (bp)’ to ‘-1000’, and then click ‘Import’. This creates a 
new data track for each sample where only the first base of each read (i.e. the 
point of viral integration) is displayed. 
55. Remove the original data tracks: click on the ‘Change Data Tracks’ icon, 
highlight the original data files in the ‘Displayed Tracks’ window, and click 
‘Remove’ button followed by the ‘OK button.  
 
56. Segment the genome into a set of equally-sized intervals and quantitate the 
number of unique lentiviral integration sites in each window. From the ‘Data’ 
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tab, choose ‘Define Probes’ and highlight ‘Running Window Generator’ from 
the ‘Probe Generator Options’ list.  
57. Set ‘Probe Size (bp)’ to ‘10000’ and the ‘Step Size (bp) to ‘5000’. Then click 
the ‘Create Probes’ button. This divides the genome into a set of 10 kb 
intervals which overlap by 5 kb. 
58. To count the number of integration sites in each window, highlight ‘Read 
Count Quantitation’ from the ‘Quantitation Options’ list. Ensure that the 
‘Correct for total read count’ and ‘Log Transform Count’ boxes are checked, 
and click ‘Quantitate’.   
 
59. Visualize data as a scatter plot and allow normalization. From the ‘Plots’ tab, 
select ‘Scatter Plot’.  
60. Select the two relevant datasets to compare, for example wild-type on the x-
axis and mutant on the y-axis. Each dot on the resulting plot represents the 
quantitation for one 10 kb genomic interval. Dots lying on the diagonal 
represent intervals containing equal frequencies of viral integration in both 
conditions.  
61. The majority of the dots should lie along the diagonal. Because the data has 
been collapsed into a set of unique integration sites, skewing of the data away 
from the diagonal may be observed at the top end of the distribution. If this is 
observed, normalize the data by clicking on the ‘Data’ tab, select ‘Quantitate 
Existing Probes’, and then highlight ‘Match Distribution Quantitation’ from the 
list of ‘Quantitation Options’. Select the two datasets to normalize on the ‘Data 
Stores to Normalise’ list on the right, and then click the ‘Quantitate’ button. 
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Re-display the scatter plot to verify that the normalization has been 
successfully applied.    
 
62. Identify loci exhibiting significant changes in lentiviral accessibility. From the 
‘Filtering’ tab, choose ‘Filter by Statistical Test’, then ‘Intensity Difference’ and 
‘Individual Probes’.  
63. In the resulting dialog box, select the relevant datasets to compare. The 
control (eg. wild-type) dataset should be selected in the first list called ‘From 
Data Store / Group’, and the experimental (eg. mutant) dataset should be 
selected in the second list called ‘To Data Store / Group’. Maintain the default 
parameters on the right, and click ‘Run Filter’. 
 
64. To visualize the loci exhibiting significant changes in lentiviral accessibility re-
create the scatter plot by following the instructions in steps 59 and 60. 
65. Then click on the ‘Highlight Sublists’ button in the top right corner. From the 
‘Available Lists’ list, highlight the entry that begins ‘Intensity Difference p<0.05’ 
and click ‘Add’ followed by ‘OK’. The scatter plot now shows loci exhibiting 
significantly altered accessibility in the experimental versus the control 
datasets colored in blue.  
66. Export the scatter plot by clicking on the ‘Save Image’ button.  
 
67. Finally, a summary of the data can be exported for further analysis. On the list 
on the left-hand side of the home screen, under ‘Probe Lists’ click on the icon 
next to ‘All Probes’ to expand the display and highlight the list of significant 
loci by clicking on it. 
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68. Under the ‘Reports’ tab, select ‘Annotated Probe Report’. 
69. In the resulting dialog box, under ‘Annotate with’ select ‘overlapping’ from the 
left-hand menu and ‘gene’ from the right-hand menu, and then click ‘OK’.  
70. The ‘Annotated Probe Report’ can then be saved and further manipulated in 
standard programs such as Microsoft Excel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
? TROUBLESHOOTING 
Troubleshooting advice can be found in Table 2. 
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TABLE 2 | Troubleshooting table. 
Step Problem Possible reason Solution 
14 Low efficiency 
transduction 
observed by flow 
cytometry  
Inefficient viral 
packaging in HEK 293T 
cells 
Thaw a fresh aliquot of HEK 
293T cells and verify that they 
are free of Mycoplasma 
infection. Passage the cells 
every 2 days and do not allow 
them to become over-confluent.
Prepare fresh plasmid stocks of 
the lentiviral vectors. 
  
14 Low efficiency 
transduction 
observed by flow 
cytometry 
Target cells refractory to 
lentiviral transduction 
Verify that high-titre lentiviral 
stocks have been generated by 
performing a parallel 
transduction of a cell line that is 
readily transducible, for 
example HEK 293T or HeLa. 
16 Inefficient 
digestion of 
genomic DNA 
Addition of too much 
DNA to the digestion 
reaction 
If the genomic DNA samples 
are “stringy”, dilute them further 
in DNA hydration solution prior 
to measuring their 
concentration. Take duplicate 
nanodrop readings of the 
genomic DNA samples and 
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verify that the readings are 
similar. 
25 Low sample 
volumes after the 
linear PCR 
Evaporation during the 
PCR reaction 
Avoid placing samples in the 
outer tubes of the PCR strip. 
Instead add 200 µl water to 
outer tubes. Ensure PCR strips 
are tightly capped. 
42 No peaks detected 
in the Bioanalyzer 
trace 
Could result from failure 
at any step of LAM-PCR 
protocol 
Efficient NlaIII digestion of 
genomic DNA can be verified 
by agarose gel electrophoresis 
of the digested DNA; this 
should generate a smear with a 
mean fragment size ~200bp. 
Efficient adaptor ligation can be 
verified by a simple PCR 
reaction using the adaptor-
ligated DNA (from Step 24) as 
the template with a single 
primer that will anneal to the 
adaptor ligated on to both ends 
of the fragments (eg. P7-
Adaptor_R; Table 1). Using 
standard cycling conditions (eg. 
30 cycles of those described in 
Step 36), the product should 
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appear as a bright smear 
should when observed by 
agarose gel electrophoresis. If 
both of these steps have 
worked correctly, then repeat 
the LAM-PCR, bead annealing 
and exponential PCR steps of 
the protocol. 
43 Failed Illumina 
sequencing run 
Low complexity  Correct library preparation 
should result in a complex 
library with approximately even 
representation of each base 
across the read. Problems with 
low complexity indicate an 
excessive amount of adaptor 
artefacts. In this case it would 
be advisable to repeat the 
LAM-PCR procedure, verifying 
efficient NlaIII digestion by 
agarose gel electrophoresis 
and adaptor ligation by PCR 
prior to the LAM-PCR steps. 
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• TIMING  
Steps 1-7, generation of lentivirus stocks: 3 days 
Steps 8-14, lentiviral transduction of target cells: 3 days 
Steps 15-43, LAM-PCR amplification of virus-genome junctions: 5 days  
Steps 44-70, Bioinformatic analysis of Illumina sequencing data: <1 day 
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ANTICIPATED RESULTS 
Transduction of target cells. We recommend using a lentiviral vector which 
encodes a fluorescent marker, which enables the transduction of the target cells to 
be assayed by flow cytometry (Step 14). If high efficiency transduction of the target 
cells has been achieved, then ~100% of the cells should be positive. An example of 
successful transduction of wild-type and mutant HeLa cells with the pHRSIN-PSFFV-
mCherry lentiviral vector is shown in Fig. 4a. 
 
LAM-PCR preparation of Illumina sequencing libraries. For HeLa cells, in step 15 
the total amount of DNA extracted from the entire 6-well plate of transduced cells 
should be approximately 200 μg. Following successful digestion with NlaIII, the vast 
majority of the genomic DNA should be fragmented to < 1 kb and can be visualized 
as a smear by agarose gel electrophoresis (Fig. 4b). After size-selection for large 
DNA fragments in steps 18-22, the amount of DNA recovered should be 
approximately 20-30% of the total input digested DNA. Successful LAM-PCR 
amplification of virus-genome junction can be assayed through Agilent Bioanalyzer 
analysis of the final Illumina library; we would expect the Bioanalyzer trace in step 42 
to look similar to that shown in Fig. 4c, with the trace starting at ~220 bp, peaking at 
~240 bp, and then gradually tailing off by ~600 bp.   
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Bioinformatic analysis of Illumina sequencing data. Any abnormalities with the 
sequencing data should be revealed by Fastqc at step 45. Efficient amplification of 
virus-genome junctions should result in approximately even representation of each of 
the four bases across the sequence reads; strong bias in base representation is 
indicative of adaptor artefacts.  
Based on downsampling analysis of our DIVA Illumina sequencing data9 
(Figure 3), we found that approximately 10 million uniquely mapped reads per 
condition would have been sufficient to draw meaningful conclusions from the 
experiment. Therefore, for high coverage of a large mammalian genome, we 
recommend that >10 million uniquely mapped reads in each of the control and 
treated samples should be obtained at steps 43-47. Useful data may still be derived 
from samples with lower coverage, however, although an increased number of loci 
exhibiting a significant change in accessibility would likely be uncovered as more 
uniquely mapped reads are generated (Figure 3d).    
The overall aim of this protocol is to identify genomic loci exhibiting altered 
chromatin accessibility between control and treated cells. A scatterplot (steps 59 and 
60) summarizing the results of a DIVA experiment is shown in Figure 4d. At the 
completion of a successful experiment the researcher should have derived a list of 
genomic sites (tabulated in steps 67-70) which show significantly altered accessibility 
between the two cell types. 
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FIGURE LEGENDS 
Figure 1 | Conceptual overview of DIVA. DIVA examines the integration 
preferences of exogenous lentiviruses to infer changes in chromatin accessibility 
between control (wild-type) and treated (mutant) cells. 
  
Figure 2 | Workflow of a DIVA experiment.  
(a) Lentiviral transduction of target cells. Lentivirus is generated through the triple 
transfection of HEK-293T cells, and the viral supernatant is used to transduce the 
matched pair of control and treated target cells. 
(b) Mapping of lentiviral integration sites. Genomic DNA harvested from the 
transduced cells is enzymatically digested and adaptor ligated, followed by linear 
PCR amplification of virus-genome junctions. Biotinylated linear PCR products are 
captured on streptavidin beads which are then used as the template for a final 
exponential PCR to generate a library for Illumina sequencing. 
(c) Bioinformatic analysis of Illumina sequence data. Illumina reads are mapped to 
the reference genome to define a set of unique lentiviral integration sites in each cell 
type (control vs treated); comparing the pattern of integration sites in control (wild-
type) versus treated (mutant) cells reveals genomic loci exhibiting altered chromatin 
architecture.  
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Figure 3 | Genome coverage and sequencing depth required for DIVA.  
(a) Comparison of the genomic coverage obtained with DIVA and ATAC-seq. The 
bar chart indicates the percentage of either ATAC-seq peaks (blue) or unique 
lentiviral integration sites identified by DIVA (orange) that occur across 15 types of 
chromatin. Compared to ATAC-seq, lentiviral integration sites are depleted from 
transcriptional start sites and enhancers, and are instead enriched in gene bodies 
and intergenic regions. ATAC-seq peaks were from10, DIVA lentiviral integration sites 
were from9, and the chromatin state classifications were from20.  
(b-d) Sequencing depth required for DIVA. (b) Downsampling analysis of Illumina 
sequencing data for wild-type HeLa cells9. Whilst the proportion of uniquely mapped 
reads scales linearly with the total number of sequencing reads generated, the 
number of unique integration sites detected plateaus rapidly. Thus, further 
sequencing of these DIVA libraries would have yielded few additional unique 
integration sites. (c) The maximal correlation between wild-type and mutant samples 
was essentially achieved with 10 million uniquely mapped reads per condition, and 
did not improve further with the addition of more reads. (d) Quantification of the 
number of genomic loci exhibiting a significant change in accessibility as a function 
of sequencing depth. The number of significant loci continues to increase as the 
number of mapped reads increases; in our experiment, however, similar biological 
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conclusions could have been drawn with 10 million uniquely mapped reads per cell 
type.  
 
 
 
Figure 4 | Anticipated results of a DIVA experiment. 
(a) Successful lentiviral transduction of target cells. Transduction of wild-type and 
mutant cell lines with high-titer virus should result in ~100% infection; this can be 
easily monitored by flow cytometry if the virus used expresses a fluorescent protein.  
(b) Efficient digestion of genomic DNA with NlaIII as visualized by 2% agarose gel 
electrophoresis. Molecular weight markers are shown in lanes 1, 3 and 5. A broad 
smear should be observed with fragments ranging from ~100 bp to ~ 2 kb in both cell 
types. 
(c) Validation of successful Illumina library generation. Using the pHRSIN-PSFFV-
mCherry lentiviral vector with NlaIII digestion, Agilent Bioanalyzer analysis of the 
final exponential PCR product should reveal a trace starting at ~220 bp, peaking at 
~240 bp, and then gradually tailing off by ~600 bp. A similar profile should be 
observed in both cell types. 
(d,e) Results of a successful DIVA experiment. Each point on the scatterplot (d) 
indicates the correlation between the number of unique lentiviral integrations 
detected in the wild-type cells versus the mutant cells for a given 10 kb genomic 
locus. Loci exhibiting a significant change in accessibility between the wild-type and 
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mutant samples are highlighted in blue. Raw data for one locus of interest (ZFN772) 
is depicted in (e), comparing the coverage achieved using DIVA and ATAC-seq. 
ATAC-seq transposon integrations are concentrated at the transcriptional start site, 
whereas DIVA lentiviral integration sites are found predominantly across the body of 
the gene. A greater number of unique integration sites are detected across the body 
of the gene in the mutant sample, indicating an increase in chromatin accessibility in 
the mutant cell line.    
Box 1 | Size-selection of large DNA fragments containing virus-genome 
junctions. 
During steps 18-22 of the protocol, a size-selection is performed to enrich for large 
DNA fragments following NlaIII digestion of the genomic DNA. The diagram (inset) 
shows the location of NlaIII recognition sites in the pHRSIN-PSFFV-mCherry lentiviral 
vector when integrated into genome, plus the primer binding sites for PCR 
amplification of the virus-genome junction. The distribution of NlaIII sites is such that 
a genomic DNA fragment containing the 5’LTR must be at least ~1.8 kb; therefore, 
selecting for large DNA fragments enriches for the fragments of interest that contain 
proviral DNA. The distribution of restriction sites in the proviral DNA is therefore an 
important consideration should the protocol be adapted to use alternative lentiviral 
vectors or restriction enzymes. Abbreviations are as follows: LTR, long terminal 
repeat; WPRE, Woodchuck Posttranscriptional Regulatory Element; PSFFV, spleen 
focus-forming virus promoter. 
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